BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 32430507)

  • 21. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
    Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
    Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature.
    Foster WR; Bischin A; Dorer R; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):311-21. PubMed ID: 27234438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
    Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
    Matsuda S; Suzuki R; Takahashi T; Suehiro Y; Tomita N; Izutsu K; Fukuhara N; Imaizumi Y; Shimada K; Nakazato T; Yoshida I; Miyazaki K; Yamaguchi M; Suzumiya J
    Int J Hematol; 2020 Dec; 112(6):807-816. PubMed ID: 32880824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R
    Haematologica; 2021 Mar; 106(3):730-735. PubMed ID: 32107337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
    Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
    J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis.
    Shah NN; Harrison N; Stonecypher M; Frank D; Amorosa V; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e157-60. PubMed ID: 25027567
    [No Abstract]   [Full Text] [Related]  

  • 30. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-intensity therapy in adults with Burkitt's lymphoma.
    Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
    N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
    Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
    J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
    Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
    J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8.
    Hansen PB; Penkowa M; Kirk O; Skinhøj P; Pedersen C; Lisse I; Kiss K; Zhou X; Hamilton-Dutoit SJ
    Eur J Haematol; 2000 Jun; 64(6):368-75. PubMed ID: 10901590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
    David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma.
    Lamar ZS; Fino N; Palmer J; Gruber L; Morris BB; Raetskaya-Solntseva O; Kennedy L; Vaidya R; Hurd D; Zamkoff K
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):76-81. PubMed ID: 26725264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
    Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
    J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.